UBC offers the computerized CDR System to assess the major aspects of cognitive function known to be influenced by medicines and disease, including attention/ concentration, short- term working memory and long-term episodic secondary memory.
The CDR System can be utilized in any clinical setting and with any population, throughout the drug development process, from first-in-man trials to global trials during phase III and IV. The CDR System has been used in over 1,000 trials and has been cited in well over 250 publications and 456 published conference abstracts.
UBC has experience in over 47 therapeutic categories including schizophrenia, sleep medicines, coronary artery bypass graft (CABG) surgery, dementia, ADHD, Parkinson's disease and stroke. Responses to a standardized battery of tasks are measured with true millisecond precision using our proprietary YES/NO Response box, allowing a typical comprehensive cognitive profile to be obtained in around 18 minutes. The system does not require administration by specialist staff. The core battery of assessments can be supplemented with a variety of other tests which are either fully computerized or computer assisted. All data are recorded automatically and securely, and correlated with our large normative database to assess effects.
